From our survey

What esketamine's FDA approval does and does not tell a skeptic

If you are skeptical of ketamine therapy, someone has probably told you, "But it's FDA-approved." That sentence is partly right, and the part that is wrong matters. This explainer walks through what esketamine's approval actually covers, what it leaves out, and what a careful skeptic should still ask.

The FDA question clearly weighs on people. When our summer poll asked 443 adults in ten Midwest states about it, three in five said the FDA's verdict would weigh heavily, or decide outright, whether they tried a new depression drug, and roughly a fifth reacted to the idea of ketamine therapy with skepticism. The totals are whole-sample and final.

What was approved

The FDA approved esketamine, sold under the brand name Spravato, in nasal spray form for adults who have gone through adequate antidepressant trials and remain depressed. Approval means the FDA reviewed clinical evidence and concluded that, for that population and use, the benefits outweighed the risks.

Esketamine is a close chemical relative of ketamine. It is not the same product that clinics give by IV, and it is not the same as the tablets or lozenges some telehealth services send to people's homes.

What the approval tells you

It was reviewed for depression. Unlike generic ketamine, which is approved as an anesthetic and used off-label for depression, esketamine went through the FDA's review for a depression indication specifically.

It came with conditions. The approval includes a Risk Evaluation and Mitigation Strategy, or REMS. Under it, esketamine can only be given at certified healthcare settings. You use the spray while a staff member watches, then stay put, observed, for a couple of hours at minimum. Driving and machinery wait until tomorrow, and no doses leave the building. Brain Recovery Centers describes the Spravato visit step by step if you want to picture it.

The risks are known and named. The label describes risks including sedation, dissociation (a feeling of detachment from your body or surroundings), increases in blood pressure, and the potential for misuse. The REMS exists because of those risks. For a skeptic, that can be read two ways: as a warning, or as evidence that the risks are taken seriously enough to be managed on every dose.

What the approval does not tell you

It does not tell you whether it will work for you. Approval reflects results across a studied group. Individual responses vary, and some people do not benefit.

It does not cover other ketamine. Infused IV ketamine for depression falls outside the approval, as do home-use ketamine products, both used off-label and the latter sometimes compounded. Compounded products are not FDA-approved at all. When someone says "ketamine is FDA-approved" in a depression context, ask which product they mean.

It does not approve clinics. The FDA reviews products. It does not endorse any clinic. A certified esketamine site is certified to administer that product under the REMS, which is specific and real, but it is not a general FDA seal on the practice.

It does not cover every condition. Esketamine's approval is for depression, not for PTSD or anxiety disorders. If a provider suggests it for something outside the approved use, that is off-label, and you are entitled to ask why.

It does not settle whether you are a candidate. Certain health conditions, such as some blood vessel problems or a history of certain reactions, can make esketamine inappropriate. Only a clinician reviewing your history can judge that.

What the approval does not settle about cost

Approval does not promise coverage, and plans typically want prior authorization with records of earlier antidepressant trials. Our respondents put this ahead of FDA status: 85 percent listed insurance among their two main provider priorities, compared with just over a quarter for FDA approval.

A skeptic's reasonable questions

• "Is the treatment you're suggesting esketamine specifically, or another form of ketamine?"
• "Is my use on-label? If not, why this instead of an approved option?"
• "What happens during the monitoring period, and what side effects should I expect?"
• "What would make me a poor candidate?"
• "How will we decide whether it's working, and when would we stop?"
• "What are my alternatives, including ones that don't involve medication?"

If you would rather not take a medication

Being skeptical of esketamine is a perfectly reasonable position after you have the facts. You may prefer an option that involves no drug at all. Sixty-four percent of our respondents said they cared about having a drug-free option. TMS delivers magnetic pulses through a scalp coil with no medication, and its devices are FDA-cleared for adults still depressed after antidepressants. Psychotherapy is another drug-free path.

Why so few people know this

Awareness of the approved product is remarkably low. Almost three in four of our respondents had never run across the name Spravato, and 6 percent could describe it, which makes it easy for approved and unapproved ketamine to blur together in conversation and in headlines.

Where to take your questions

Your own doctor. In our survey, 74 percent would try a new treatment on the strength of that doctor's recommendation. A good doctor will welcome skeptical questions and answer them precisely. In the meantime, do not drop a current medication on your own; plan any change with the prescriber.

No regular doctor? A psychiatrist or another mental health professional works as a starting point too. Our respondents divided the same way: 56 percent would open with a family physician, 23 percent with psychiatry, and 12 percent would research online alone. Given how easily the forms of ketamine blur, a clinician is the better guide.

Skepticism about a drug should never keep you from crisis support. With thoughts of suicide, the Suicide and Crisis Lifeline is free at 988 by call or text, any hour.

Methodology

Pollfish ran the study (number 395586438) on its consumer panel from launch through June 23, 2026. It captured 443 adults, 18 to 64, living in Iowa, Missouri, Kansas, Wisconsin, Ohio, Nebraska, Oklahoma, Indiana, Illinois and Minnesota, all of whom agreed at a consent screener. What we publish is the final, validated tally. The publisher commissioned the poll and covered its expense.